Check here for our latest news, press releases, and publications.
Check here for our latest news, press releases, and publications.
Ethypharm strengthens its commitment to pain by participating in a solidarity race in France for the benefit of the NGO « Douleurs Sans Frontières »
As part of the Group partnership with the NGO « Douleurs Sans Frontières / Pain Without Boarders », Ethypharm France will participate in « La Course des Héros / the Heroes Race ». What is the Heroes race? It is a French solidarity event that raises funds for the benefit of an Association whose fight is close to their heart. This year, the Ethypharm Group strengthens its commitment to Pain and so supports the Association DSF (Douleurs Sans Frontières / Pain Without Borders). On this occasion all Ethypharm employees in France and their families, are invited to participate in this sporting and solidarity event. We are Ethypharm!
On the occasion of their annual the“Prescrire” magazine recognized Les Laboratoires Ethypharm
Since January 1981, Prescrire a French monthly independent medical journal publishes the news of diseases, drugs and medical techniques and technologies.
Its purpose is to provide to and through healthcare professionals and patients, the clear, synthetic and reliable information they need on drugs, diagnostic and therapeutic strategies.
On the occasion of their annual awards by the end of January, the “Prescrire” magazine recognized Les Laboratoires Ethypharm with two distinctions for Prenoxad® kit, indicated in the management of opiate overdoses.
Les Laboratories Ethypharm were named in the category of « honourable company », which reflects how each firm assumes responsibility for sharing information with the journal.
Although no “Gold Pill” was given this year, the naloxone kits were particularly highlighted during this edition. PRENOXAD (which launch is planned in Q1/Q2 2019), was named in this category.
Even if their impact is considered to be modest, the drugs named in the rankings help to improve the means of taking care of patients.
2019 marks a turning point with an acceleration of the availability of addiction medicines in France. The wide availability of naloxone is one of the priority guidelines set by the health authorities in France. The obtaining of two awards given by the independent journal “Prescrire”, testifies Ethypharm’s commitment in this field to reduce risk and damage.
Ethypharm is Granted Marketing Authorisation for Its Drug Baclocur®
The National Agency for the Safety of Medicines and Healthcare Products (ANSM) has just granted Ethypharm marketing authorisation for its drug Baclocur® in France.
Ethypharm GmbH was successfully present at Expopharm in Munich
From October 10 to 13, Ethypharm GmbH was successfully present at Expopharm in Munich. At this important European pharmaceutical trade fair, our team met many key decision-makers from all sectors of the pharma industry to expand our business in Germany.
Ethypharm had a great show at CPHI 2018
Ethypharm was at the CPHI 2018 which took place in Madrid.
The Business Development, Global Channel Sales, Corporate Development, Procurement teams and our subsidiaries teams in the UK, Germany, China, USA & Canada, attended the event to exchange and foresee new business opportunities for our Group.
Ethypharm Germany has a new website!
This website is the result of a transverse work between the teams of Ethypharm Germany and the Corporate Communications department. Stay tuned to discover in the coming months the specific features of the German subsidiary such as products, tender, etc…
Go to www.ethypharm.de to learn more our German teams, our local business and our products. WIR SIND ETHYPHARM!
World Clean Up Day
The employees of the Ethypharm Group mobilized during the World Clean Up Day and gathered several dozen kilos of waste. Thank you to all the teams who volunteered to clean the world in one day. We’re committed, we are Ethypharm !
Ethypharm announces the appointment of Emmanuel SCHMIDT as CFO
St-Cloud, France –September 4th, 2018
Emmanuel SCHMIDT has been appointed Chief Financial Officer and Senior Vice President of Ethypharm Group. He holds a Master of Science in Business Management of EDHEC Lille.
With twenty years’ experience serving as CFO for major international groups, Emmanuel has a 360° vision of his function. Having spent 8 years as CFO of Pierre Fabre Pharma division, he possesses an in-depth knowledge of the pharmaceutical industry and also has a great command of the LBO mechanisms acquired at Elior and Star’s Service. Since 2010, Emmanuel worked as the CFO of the Star’s Service Group.
Ethypharm appoints Frédéric MOLIN to lead its Corporate Development
St Cloud, France – 19th June 2018
Ethypharm is pleased to welcome Frédéric MOLIN to Ethypharm Group as Executive Vice President Corporate Development.
Frédéric MOLIN will be responsible to initiate and lead strategic development programs encompassing in-licensing, partnerships and M&A.
Frédéric is a Pharmacist and holds a Master’s Degree in Strategy and Marketing. He brings a wealth of experience and expertise in Business Development and in-Licensing.
Ruud Helwig is appointed Managing Director of Ethypharm GmbH
St.Cloud – France, March 1, 2018.
We are pleased to announce the appointment of Ruud Helwig to the position of Managing Director of our German subsidiary – Ethypharm GmbH.
Ruud is an agile and entrepreneurial person with a multicultural background as he has lived and worked in many countries. Of Dutch nationality, Ruud lives today in Austria and holds a Master of Business Administration, a Master of Law and Economics and a Law Practice program of IMADEC University in Vienna.
With over 34 years of experience in the pharmaceutical industry Ruud Helwig has been involved in the commercial growth and development of international companies with markets all over the world. Among these are renowned companies such as Eli Lilly, Aspen and SkyePharma.
His broad international business development experience and strong knowledge of the pharma industry in Europe, are key to build and grow our German Subsidiary.
As Managing Director of Ethypharm Germany, his main tasks include the development and creation of new growth projects aligned to the Group’s strategy. Among his responsibilities are the developing of promotional programs for our medicines, preparing specific portfolio product launches and initiating In-Licensing activities.
Ruud will be based close to Berlin, where our German subsidiary was founded back in 2015 with first sales in March 2016.
Integration of Partnered and International Sales Groups – Eric Vick is appointed Vice President of Global Channel Sales
St. Cloud – France, February 9, 2018
The successful integration of Ethypharm and Martindale since the merger in February 2017 has allowed us to form a company with greater global reach than ever before. We have begun the process of cross selling Ethypharm and Martindale products and examples such as the launch of Noyada in France or Esomeprazole growth in the UK have shown us to be better together. The International businesses have also been able to find new opportunities to take products such as Fencino and Zomorph into markets in MENA.
Ethypharm Group has assessed options for managing the business derived via our non-direct sales channels, and has decided to establish a new group, Global Channel Sales.
Global Channel Sales will encompass our growing list of distributors, license partners, and NGOs, generating sales across 80+ countries. Our goal is to develop an organisation that can leverage our local expertise, proactively manage our established business relationships, and identify new growth opportunities. With a target budget in excess of €140mn in 2018, the performance of the new group will be a core component of the overall Ethypharm Group success.
Eric Vick has been appointed as Vice President of Global Channel Sales. Eric brings to this role a strong pedigree in global sales management, a customer-focused business approach, and a drive to achieve the full potential of the business.
Beverley Thompson has joined Ethypharm as HR Director UK
Saint-Cloud- France, 22 January 2018
We are pleased to welcome Beverley Thompson as HR Director for Ethypharm UK.
As a member of the UK Leadership team, she will be responsible for business and management support for Human Resources and Communication.
Beverley has a BSc. (Hons) in Biological Sciences from Leicester University and post graduate teaching qualifications from Manchester University. She worked successfully as a teacher for a number of years and then made a change in career to join the pharmaceutical industry.
She joined Abbott Laboratories as a Medical Sales Representative and progressed her career within Abbott in Training Manager, Regional Sales Manager and HR Manager UK roles prior to taking a HR & Development Director role for Serono, initially covering the UK and then also Northern European. In 2000 she set up her own HR Consultancy and has since worked in pharmaceutical and other business sectors providing HR support to both large and small businesses. In 2016 she made a decision to move back into a company role and joined the UK FTSE 250 organisation, Berendsen plc, as a HR Director supporting their Workwear business across the UK, Scandinavia and Europe.
Charlotte Haas is appointed Chief Transformation Officer
Saint-Cloud – France, 7 December 2017
The pharmaceutical industry worldwide is undergoing a rapid, radical transformation and for some years the Group has been facing increasing and fast-growing competition. The Ethypharm Group must therefore develop rapidly and adapt its product portfolio, the direction of its R&D and its operating methods so as to ensure its growth and strengthen its financial solidity and competitive edge.
To head the programme of actions to be undertaken and decisions to be made dynamically and pragmatically, we have decided to give Ethypharm a Chief Transformation Officer.
Charlotte Haas, who has headed the strategic development of specialty products for the past six years, will now use her skills, knowledge of our field and personal energy for the growth and transformation of the group.
Throughout her career, Charlotte has gained expertise in the challenges facing the pharmaceutical industry, our competitive environment, our know-how and our three therapeutic areas (pain, addiction and critical care).
As Chief Transformation Officer, Charlotte will aim to stimulate and bolster the development of the Ethypharm Group, exploring all avenues leading to durable, responsible growth. Charlotte will be a member of the Executive Committee working transversally with all the teams of the Group.
Ethypharm was honoured receiving the gold award in the category of “Best Management Team & MBO”
At the 7th edition of the “Private Equity Exchange Awards”, Ethypharm was honored receiving the Gold Award in the Category of “Best Management Team & MBO”. Congratulations to the teams involved. We are Ethypharm!
Kindness Day 2016
At Ethypharm we celebrated the International Kindness Day under the theme “Building Team Spirit”. At Ethypharm we promote a work culture that prioritizes development of talents and wellbeing. We are Ethypharm!
The new website of Ethypharm UK is online
The new website of our subsidiary Ethypharm UK is online! We invite you to discover Ethypharm UK!
PAI Partners is the new shareholder of Ethypharm
The 21st of July, PAI Partners became officially the new shareholder of Ethypharm.
Ethypharm Shanghai celebrates its 20th anniversary
The President of France met with Ethypharm employees today.